The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma

[1] Banchereau J(2000)Immunobiology of dendritic cells Annu Rev Immunol 18 767-811

[2] Briere F(2006)Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) Blood 108 2655-2661

[3] Caux C(2006) and after injection of cytokine-matured DCs in myeloma patients Blood 107 3940-3949

[4] Davoust J(2006) peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma Clin Exp Immunol 144 76-84

[5] Lebecque S(2009)Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma Acta Haematol Pol 40 753-782

[6] Liu YJ(2010)Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma Leuk Res 34 1330-1335

[7] Pulendran B(2006)The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma – a report by the Polish Myeloma Study Group Leukemia 20 1467-1473

[8] Palucka K(2000)International uniform response criteria for multiple myeloma J Immunol 165 6037-6046

[9] Banerjee DK(2009)BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood Leukemia 23 1771-1778

[10] Dhodapkar MV(1997)Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia Blood 90 3245-3287

[1] Banchereau J(2000)Immunobiology of dendritic cells Annu Rev Immunol 18 767-811

[2] Briere F(2006)Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) Blood 108 2655-2661

[3] Caux C(2006) and after injection of cytokine-matured DCs in myeloma patients Blood 107 3940-3949

[4] Davoust J(2006) peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma Clin Exp Immunol 144 76-84

[5] Lebecque S(2009)Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma Acta Haematol Pol 40 753-782

[6] Liu YJ(2010)Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma Leuk Res 34 1330-1335

[7] Pulendran B(2006)The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma – a report by the Polish Myeloma Study Group Leukemia 20 1467-1473

[8] Palucka K(2000)International uniform response criteria for multiple myeloma J Immunol 165 6037-6046

[9] Banerjee DK(2009)BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood Leukemia 23 1771-1778

[10] Dhodapkar MV(1997)Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia Blood 90 3245-3287